These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7031389)

  • 21. A comparative study of four rodent systems to monitor initial therapy of lepromatous leprosy: in search of a more sensitive system to assess bacterial viability.
    Gelber RH; Humphres RC; Fieldstell AH
    Acta Leprol; 1984; 2(2-4):319-25. PubMed ID: 6398591
    [No Abstract]   [Full Text] [Related]  

  • 22. Experimental and clinical studies on rifampicin in treatment of leprosy.
    Rees RJ; Pearson JM; Waters MF
    Br Med J; 1970 Jan; 1(5688):89-92. PubMed ID: 4903972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the bacteriological effect of combined treatment with rifadin, sulfamethoxypyrazine, and isoniazide in lepromatous leprosy.
    Leiber DL; Verhagen AR
    Z Tropenmed Parasitol; 1973 Dec; 24():32-5. PubMed ID: 4592434
    [No Abstract]   [Full Text] [Related]  

  • 24. Rifampicin resistant leprosy: a review and a research proposal of a pilot study.
    Ji B
    Lepr Rev; 2002 Mar; 73(1):2-8. PubMed ID: 11969122
    [No Abstract]   [Full Text] [Related]  

  • 25. Evidence for the activity of rifampin on the neuropathy of foot pad-inoculated mice with Mycobacterium leprae.
    Sebille A; Crepon MO; Guelpa CC; Grosset J
    Int J Lepr Other Mycobact Dis; 1985 Sep; 53(3):481-3. PubMed ID: 2995517
    [No Abstract]   [Full Text] [Related]  

  • 26. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae.
    Shepard CC; Levy L; Fasal P
    Am J Trop Med Hyg; 1974 Nov; 23(6):1120-4. PubMed ID: 4611256
    [No Abstract]   [Full Text] [Related]  

  • 28. Newer drugs in leprosy.
    Grosset JH
    Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2 Suppl):S14-8. PubMed ID: 11757174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycobacterium leprae persisters after treatment with dapsone and rifampicin.
    Pattyn SR; Dockx P; Rollier MT; Rollier R; Saerens EJ
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):154-8. PubMed ID: 776851
    [No Abstract]   [Full Text] [Related]  

  • 30. [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980].
    Guelpa-Lauras CC; Constant-Desportes M; Millan J; Grosset J
    Acta Leprol; 1982; (86-87):77-80. PubMed ID: 6816000
    [No Abstract]   [Full Text] [Related]  

  • 31. Multi-drug therapy of leprosy.
    Ramu G
    Indian J Lepr; 1985; 57(3):465-82. PubMed ID: 2420903
    [No Abstract]   [Full Text] [Related]  

  • 32. Activity of ascorbic acid in inhibiting the multiplication of M. leprae in the mouse foot pad.
    Hastings RC; Richard V; Christy SA; Morales MJ
    Int J Lepr Other Mycobact Dis; 1976; 44(4):427-30. PubMed ID: 798727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Committee 4: workshop on experimental chemotherapy of leprosy.
    Int J Lepr Other Mycobact Dis; 1979 Jun; 47(2 Suppl):297-303. PubMed ID: 378876
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical and bacteriological effects of rifampicin in combination with L73A in leprosy: observation for six months.
    Innami S; Leguizamón OR; Alvarenga AE
    Lepr Rev; 1975 Jun; 46(2 Suppl):169-72. PubMed ID: 1100957
    [No Abstract]   [Full Text] [Related]  

  • 35. The diagnosis and management of dapsone-resistant leprosy.
    Waters MF
    Lepr Rev; 1977 Jun; 48(2):95-105. PubMed ID: 331001
    [No Abstract]   [Full Text] [Related]  

  • 36. The treatment of leprosy today and tomorrow: the LEPRA consultation on chemotherapy.
    Browne SG
    Lepr Rev; 1977 Dec; 48(4):283-6. PubMed ID: 400810
    [No Abstract]   [Full Text] [Related]  

  • 37. Correlation of laboratory and clinical data during treatment of leprosy.
    Pattyn SR; Rollier R; Rollier MR; De Muynck A; Janssens PG; Verdoolaeghe-Van Loo G
    Ann Soc Belg Med Trop; 1972; 52(6):537-48. PubMed ID: 4574223
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug resistance in leprosy: lessons from past and future perspective.
    Gupta UD; Katoch VM
    Indian J Lepr; 1999; 71(4):451-63. PubMed ID: 10804973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
    Dhople AM; Ibanez MA
    Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifampicin for lepromatous leprosy: nine years' experience.
    Waters MF; Rees RJ; Pearson JM; Laing AB; Helmy HS; Gelber RH
    Br Med J; 1978 Jan; 1(6106):133-6. PubMed ID: 339995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.